Lytica Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $50K

  • Investors
  • 6

Lytica General Information

Description

Operator of a biotechnology company intended to develop novel peptide conjugates for next-generation Antibody-Drug Conjugates (ADCs). The company taps into a natural reserve of compounds known as antimicrobial peptides (AMPs) to develop therapeutic keys that tackle the rising problem of antibiotic resistance using their proprietary technology, they have created a novel class of antibiotics with potent activity and a reduced propensity for bacterial resistance, helping patients by providing successful therapy.

Contact Information

Website
www.lyticatherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 840 Memorial Drive
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 840 Memorial Drive
  • Cambridge, MA 02139
  • United States
+1 (617)

Lytica Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lytica Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A) 29-Sep-2026 $50K Completed Pre-Clinical Trials
5. Later Stage VC 20-Oct-2025 Completed Pre-Clinical Trials
4. Later Stage VC 11-Mar-2024 Completed Pre-Clinical Trials
3. Early Stage VC Completed Pre-Clinical Trials
2. Accelerator/Incubator Completed Pre-Clinical Trials
1. Grant 18-Feb-2020 $5.3M Completed Pre-Clinical Trials
To view Lytica’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Lytica Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop novel peptide conjugates for next-generation Antibody-Drug Conju
Drug Discovery
Cambridge, MA
10 As of 2026

San Diego, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lytica Competitors (3)

One of Lytica’s 3 competitors is Ambrx, a Formerly PE-Backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ambrx Formerly PE-Backed San Diego, CA
Mersana Therapeutics Formerly VC-backed Cambridge, MA
BioAtla Formerly VC-backed San Diego, CA
You’re viewing 3 of 3 competitors. Get the full list »

Lytica Patents

  • 25

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 18

    Pending

  • Expiring in next 12 mo

Lytica Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023406317-A1 Compositions and methods for protein internalization Pending 02-Dec-2022
EP-4626479-A1 Compositions and methods for protein internalization Pending 02-Dec-2022
JP-2025540961-A Compositions and methods for protein internalization Pending 02-Dec-2022
US-20260191983-A1 Compositions and methods for protein internalization Pending 02-Dec-2022
WO-2024119049-A1 Compositions and methods for protein internalization Inactive 02-Dec-2022 A61K47/6849
To view Lytica’s complete patent history, request access »

Lytica Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lytica Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
HBM Healthcare Investments Venture Capital Minority
HBM Partners Venture Capital Minority
Standish Spring Investments Venture Capital Minority
CARB-X University
LabCentral Accelerator/Incubator
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Lytica FAQs

  • When was Lytica founded?

    Lytica was founded in 2019.

  • Where is Lytica headquartered?

    Lytica is headquartered in Cambridge, MA.

  • What is the size of Lytica?

    Lytica has 10 total employees.

  • What industry is Lytica in?

    Lytica’s primary industry is Drug Discovery.

  • Is Lytica a private or public company?

    Lytica is a Private company.

  • What is Lytica’s current revenue?

    The current revenue for Lytica is .

  • How much funding has Lytica raised over time?

    Lytica has raised $12M.

  • Who are Lytica’s investors?

    HBM Healthcare Investments, HBM Partners, Standish Spring Investments, CARB-X, and LabCentral are 5 of 6 investors who have invested in Lytica.

  • Who are Lytica’s competitors?

    Ambrx, Mersana Therapeutics, and BioAtla are competitors of Lytica.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process